Skip to main content
Advicenne logo

Advicenne — Investor Relations & Filings

Ticker · ALDVI ISIN · FR0013296746 LEI · 969500YT5VMEYAYODW34 PA Manufacturing
Open in API
Filings indexed 259 across all filing types
Latest filing 2023-09-11 Earnings Release
Country FR France
Listing PA ALDVI

About Advicenne

https://advicenne.com

Advicenne is a specialty pharmaceutical company dedicated to developing and commercializing treatments for rare renal diseases. The company focuses on addressing unmet medical needs in nephrology for both children and adults. Its lead product, Sibnayal®, is an approved treatment for distal Renal Tubular Acidosis (dRTA). Advicenne is committed to improving the lives of patients with rare kidney conditions by developing therapeutics, including pediatric-friendly formulations, suitable for patients of all ages.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 1% confidence The document is titled "Advicenne présente ses résultats financiers semestriels au 30 juin 2023 et fait le point sur ses activités" (Advicenne presents its half-year financial results as of June 30, 2023, and provides an update on its activities). It contains detailed financial tables (P&L, cash flow) for the first half of the year (S1 2023 vs S1 2022), management commentary on performance, and updates on clinical trials and commercial progress. This structure is characteristic of a comprehensive report covering a period shorter than a full year, which aligns with the definition of an Interim / Quarterly Report (IR). Although it mentions the full 'Rapport Financier Semestriel' is available elsewhere, the content provided here is the substance of that report, not just a brief announcement (RPA/RNS). It also mentions an associated capital increase, but the primary focus is the half-year financial performance. H2 2023
2023-09-11 French
Informations privilégiées / Autres communiqués
Earnings Release Classification · 1% confidence The document is a press release dated July 12, 2023, announcing the company's financial performance for the first half of 2023 (S1 2023). It details key financial metrics, specifically revenue growth (ventes brutes) and product performance (Sibnayal®). This format, focusing on period-specific financial highlights released shortly after the period ends, aligns perfectly with an Earnings Release (ER). It is not a comprehensive Annual Report (10-K) or a detailed Interim Report (IR), but rather the initial announcement of results. H1 2023
2023-07-12 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release from Advicenne dated June 14, 2023, announcing the presentation of long-term clinical results for their drug ADV7103 at upcoming scientific conferences (ERA and ESPN). It details the titles, authors, and session times for these presentations. This type of announcement, which informs the market about upcoming scientific disclosures or the publication of data, fits best under the category of a general regulatory announcement or news release that doesn't correspond to a specific financial report (like 10-K, ER, or IR). Since it is not a full report, but an announcement about where data will be presented, and it doesn't fit the specific criteria for Director's Dealing (DIRS), Dividend (DIV), or Capital Change (CAP), the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory news.
2023-06-14 French
Inside Information / Other news releases
Legal Proceedings Report Classification · 1% confidence The document is a press release from Advicenne announcing the scientific communication program for the results of their clinical development program (ADV7103). It details which results will be presented at upcoming scientific conferences (ERA and ESPN) and includes contact information and a standard disclaimer. This type of announcement, which communicates future plans for presenting data rather than releasing the full financial report or a transcript of a call, fits best under the general category for regulatory announcements or investor communications that don't match a more specific type like 10-K, ER, or CT. Since it is an announcement about scientific data presentation rather than a formal financial report or a management change, and it is not a proxy statement or dividend notice, the most appropriate classification is Regulatory Filings (RNS) as a general regulatory/investor announcement, or potentially Investor Presentation (IP) if the focus was solely on the presentation content, but RNS serves as a better catch-all for press releases detailing future data dissemination.
2023-06-14 English
Inside Information / Other news releases
AGM Information Classification · 1% confidence The document explicitly announces the results of the 'Combined General Meeting of shareholders' held on June 8, 2023. It details that all resolutions supported by the Board were adopted, except for the 22nd resolution, and mentions the reappointment of the Chairman post-meeting. This content directly relates to the official outcomes of a shareholder vote, which corresponds to the Declaration of Voting Results & Voting Rights Announcements category (DVA). Although it mentions the AGM, the focus is on the *results* of the vote, not the presentation materials (AGM-R) or proxy solicitation (PSI). The document is a press release announcing these results.
2023-06-09 English
Informations privilégiées / Autres communiqués
AGM Information Classification · 1% confidence The document is a press release titled "Advicenne annonce l'approbation de l'ensemble des résolutions soutenues par le Conseil d'administration lors de son assemblée générale mixte" (Advicenne announces the approval of all resolutions supported by the Board of Directors at its combined general meeting). It explicitly states that the combined general meeting of shareholders took place on June 8, 2023, and details the results of the votes on various resolutions (approving accounts, renewing mandates, etc.). This content directly relates to the proceedings and outcomes of an Annual General Meeting (AGM). Although it reports the results, the primary focus is the meeting itself, making AGM-R the most appropriate classification, rather than DVA (which is strictly the declaration of voting results). Given the context of reporting on the meeting's outcome, AGM-R is the best fit.
2023-06-09 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.